Gravar-mail: Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]